Epithelial–mesenchymal transition inhibition by metformin reduces melanoma lung metastasis in a murine model

Melanoma is an aggressive cancer with fast metastatic spread and reduced survival time. One common event during the neoplastic progression is the epithelial–mesenchymal transition (EMT), which enhances invasiveness, cell migration, and metastasis. In this study, we investigated the effects of metfor...

Descripción completa

Detalles Bibliográficos
Autores principales: Veloso, Emerson Soares, de Carvalho, Bárbara Andrade, de Souza Silva, Felipe Henrique, Ribeiro, Thaís Salviana, Lima, Bruna Mendes, Almeida, Camila Pereira, da Silva, Vítor Henrique Soares Romão, Rocha, Sara Aparecida, de Araújo Campos, Marina Rios, Del Puerto, Helen Lima, Ferreira, Enio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588059/
https://www.ncbi.nlm.nih.gov/pubmed/36273071
http://dx.doi.org/10.1038/s41598-022-22235-8
_version_ 1784814044255879168
author Veloso, Emerson Soares
de Carvalho, Bárbara Andrade
de Souza Silva, Felipe Henrique
Ribeiro, Thaís Salviana
Lima, Bruna Mendes
Almeida, Camila Pereira
da Silva, Vítor Henrique Soares Romão
Rocha, Sara Aparecida
de Araújo Campos, Marina Rios
Del Puerto, Helen Lima
Ferreira, Enio
author_facet Veloso, Emerson Soares
de Carvalho, Bárbara Andrade
de Souza Silva, Felipe Henrique
Ribeiro, Thaís Salviana
Lima, Bruna Mendes
Almeida, Camila Pereira
da Silva, Vítor Henrique Soares Romão
Rocha, Sara Aparecida
de Araújo Campos, Marina Rios
Del Puerto, Helen Lima
Ferreira, Enio
author_sort Veloso, Emerson Soares
collection PubMed
description Melanoma is an aggressive cancer with fast metastatic spread and reduced survival time. One common event during the neoplastic progression is the epithelial–mesenchymal transition (EMT), which enhances invasiveness, cell migration, and metastasis. In this study, we investigated the effects of metformin at EMT in melanoma cell lines B16-F10 and A-375, in vitro, and the impact of EMT downregulation on melanoma progression in vivo. The metformin cells treatment reduces the migration potential in vitro and reduced the development of pulmonary metastases and the expressions of N-cadherin, vimentin, ZEB1, and ZEB2 at the metastases site, in vivo. These results indicate that metformin can promote EMT downregulation impairing the metastatic potential of melanoma cells.
format Online
Article
Text
id pubmed-9588059
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-95880592022-10-24 Epithelial–mesenchymal transition inhibition by metformin reduces melanoma lung metastasis in a murine model Veloso, Emerson Soares de Carvalho, Bárbara Andrade de Souza Silva, Felipe Henrique Ribeiro, Thaís Salviana Lima, Bruna Mendes Almeida, Camila Pereira da Silva, Vítor Henrique Soares Romão Rocha, Sara Aparecida de Araújo Campos, Marina Rios Del Puerto, Helen Lima Ferreira, Enio Sci Rep Article Melanoma is an aggressive cancer with fast metastatic spread and reduced survival time. One common event during the neoplastic progression is the epithelial–mesenchymal transition (EMT), which enhances invasiveness, cell migration, and metastasis. In this study, we investigated the effects of metformin at EMT in melanoma cell lines B16-F10 and A-375, in vitro, and the impact of EMT downregulation on melanoma progression in vivo. The metformin cells treatment reduces the migration potential in vitro and reduced the development of pulmonary metastases and the expressions of N-cadherin, vimentin, ZEB1, and ZEB2 at the metastases site, in vivo. These results indicate that metformin can promote EMT downregulation impairing the metastatic potential of melanoma cells. Nature Publishing Group UK 2022-10-22 /pmc/articles/PMC9588059/ /pubmed/36273071 http://dx.doi.org/10.1038/s41598-022-22235-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Veloso, Emerson Soares
de Carvalho, Bárbara Andrade
de Souza Silva, Felipe Henrique
Ribeiro, Thaís Salviana
Lima, Bruna Mendes
Almeida, Camila Pereira
da Silva, Vítor Henrique Soares Romão
Rocha, Sara Aparecida
de Araújo Campos, Marina Rios
Del Puerto, Helen Lima
Ferreira, Enio
Epithelial–mesenchymal transition inhibition by metformin reduces melanoma lung metastasis in a murine model
title Epithelial–mesenchymal transition inhibition by metformin reduces melanoma lung metastasis in a murine model
title_full Epithelial–mesenchymal transition inhibition by metformin reduces melanoma lung metastasis in a murine model
title_fullStr Epithelial–mesenchymal transition inhibition by metformin reduces melanoma lung metastasis in a murine model
title_full_unstemmed Epithelial–mesenchymal transition inhibition by metformin reduces melanoma lung metastasis in a murine model
title_short Epithelial–mesenchymal transition inhibition by metformin reduces melanoma lung metastasis in a murine model
title_sort epithelial–mesenchymal transition inhibition by metformin reduces melanoma lung metastasis in a murine model
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588059/
https://www.ncbi.nlm.nih.gov/pubmed/36273071
http://dx.doi.org/10.1038/s41598-022-22235-8
work_keys_str_mv AT velosoemersonsoares epithelialmesenchymaltransitioninhibitionbymetforminreducesmelanomalungmetastasisinamurinemodel
AT decarvalhobarbaraandrade epithelialmesenchymaltransitioninhibitionbymetforminreducesmelanomalungmetastasisinamurinemodel
AT desouzasilvafelipehenrique epithelialmesenchymaltransitioninhibitionbymetforminreducesmelanomalungmetastasisinamurinemodel
AT ribeirothaissalviana epithelialmesenchymaltransitioninhibitionbymetforminreducesmelanomalungmetastasisinamurinemodel
AT limabrunamendes epithelialmesenchymaltransitioninhibitionbymetforminreducesmelanomalungmetastasisinamurinemodel
AT almeidacamilapereira epithelialmesenchymaltransitioninhibitionbymetforminreducesmelanomalungmetastasisinamurinemodel
AT dasilvavitorhenriquesoaresromao epithelialmesenchymaltransitioninhibitionbymetforminreducesmelanomalungmetastasisinamurinemodel
AT rochasaraaparecida epithelialmesenchymaltransitioninhibitionbymetforminreducesmelanomalungmetastasisinamurinemodel
AT dearaujocamposmarinarios epithelialmesenchymaltransitioninhibitionbymetforminreducesmelanomalungmetastasisinamurinemodel
AT delpuertohelenlima epithelialmesenchymaltransitioninhibitionbymetforminreducesmelanomalungmetastasisinamurinemodel
AT ferreiraenio epithelialmesenchymaltransitioninhibitionbymetforminreducesmelanomalungmetastasisinamurinemodel

Ejemplares similares